Analysis of 987 reports of adverse reactions to chemotherapy drug-related myelosuppression
Objective To understand the occurrence and characteristics of adverse drug reactions(ADRs)of chemotherapy drug-related myelosuppression in our hospital,and to provide a reference for the safe and rational use of chemotherapy drugs in clinical practice.Methods A total of 987 reports of ADRs related to myelosuppression due to chemotherapy drugs in our hospital were collected from January 2018 to June 2023,and the patients were analyzed in terms of age,gender,main diagnostic tumor type,grading of myelosuppression,time of myelosuppression occurrence,chemotherapy drug type,and main manifestations of myelosuppression.Results The majority of the 987 patients with myelosuppression were elderly patients.The average occurence time of myelosuppression was 4.85 days,and 8.21%of patients with severe(grade Ⅲ and Ⅵ)myelosuppression.Leucopenia was the main manifestation of myelosuppression,and plant origin and their derivatives leaded to a high proportion of severe manifestation.Conclusion Clinical pharmacists need to pay attention to the occurrence of myelosuppression caused by chemotherapeutic drugs,strengthen the supervision of chemotherapeutic drug administration,provide personalized medication advice in combination with guidelines and other literature,and provide a reference basis for safe and rational clinical use.
MyelosuppressionChemotherapeutic drugsAdverse effectsRational drug usePaclitaxel
NETL
NSTL
万方数据
